By Bill Wichert (November 20, 2020, 6:21 PM EST) -- A Johnson & Johnson unit and a private equity firm will pay a combined $11.5 million to resolve False Claims Act allegations in Pennsylvania federal court that a former J&J subsidiary had promoted a medical procedure for unapproved uses on children, prosecutors said.
J&J unit Medical Device Business Services Inc. and The Gores Group have agreed to pay $10 million and $1.5 million, respectively, over claims that Therakos Inc. improperly marketed a cancer treatment for uses not approved by the U.S. Food and Drug Administration when J&J owned the company and after the investment firm bought it, prosecutors said.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!